Patents Assigned to Immunogen, Inc.
  • Patent number: 11135305
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 5, 2021
    Assignee: ImmunoGen, Inc.
    Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
  • Patent number: 11135308
    Abstract: The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: October 5, 2021
    Assignee: IMMUNOGEN, INC.
    Inventor: Wayne C. Widdison
  • Publication number: 20210299265
    Abstract: The present invention provides a novel method for preparing a cell-binding agent cytotoxic agent conjugate. The method comprises the step of reacting a cell-binding agent with a cytotoxic agent or a cytotoxic agent-linker compound having a reactive group capable of forming a covalent bond with the cell-binding agent at a pH between 4 to 9 in the presence of a buffer solution with high ionic strength, wherein the cell-binding agent comprises a lysine ?-NH2 group that forms a covalent bond with the cytotoxic agent or the cytotoxic agent-linker compound having an amine-reactive group. The cell-binding agent-cytotoxic agent conjugates prepared according to the methods described herein are also included in the present invention.
    Type: Application
    Filed: February 3, 2017
    Publication date: September 30, 2021
    Applicants: IMMUNOGEN, INC., IMMUNOGEN, INC.
    Inventors: Katharine C. Lai, Robert W. Herbst, Scott Alan Hilderbrand
  • Patent number: 11116845
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VI). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: September 14, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Michael Louis Miller, Manami Shizuka
  • Patent number: 11090390
    Abstract: The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: August 17, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Xinfang Li, Jared M. Worful
  • Patent number: 11046762
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: June 29, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Patent number: 11033564
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: June 15, 2021
    Assignee: ImmunoGen, Inc.
    Inventors: Jose Ponte, Jan Pinkas, Rodrigo R. Ruiz-Soto
  • Patent number: 10988531
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: April 27, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Nathan Elliott Fishkin, Daniel Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V. J. Chari
  • Publication number: 20210101871
    Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
    Type: Application
    Filed: September 17, 2020
    Publication date: April 8, 2021
    Applicants: IMMUNOGEN, INC., IMMUNOGEN, INC.
    Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
  • Patent number: 10968228
    Abstract: The invention provides novel methods for preparing indolinobenzodiazepine monomer compounds of formula (I) below and their synthetic precursors:
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: April 6, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
  • Patent number: 10947315
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 16, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V. J. Chari
  • Patent number: 10944190
    Abstract: Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: March 9, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Wayne C. Widdison, Robert Yongxin Zhao
  • Patent number: 10919969
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 16, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Patent number: 10913795
    Abstract: Compositions and methods for minimizing antibody disulfide bond reduction are described. In one aspect, a composition is provided for culturing mammalian host cells to express an antibody including an anti-reduction agent that minimizes reduction of a disulfide bond in the antibody or fragment thereof. In some other aspects, methods for minimizing disulfide bond reduction; increasing production of an antibody or fragment thereof with intact native disulfide bonds; increasing a ratio of non-reduced to reduced antibody or fragment thereof; producing a therapeutic antibody or fragment thereof by adding a sufficient amount of an anti-reduction agent to a cell culture media, pre-harvest cell culture fluid, or harvest cell culture fluid are described. In another aspect, minimizing disulfide bond reduction in an antibody or fragment thereof culturing the host cell in a concentration of at least about 20% O2 is described.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: February 9, 2021
    Assignee: ImmunoGen, Inc.
    Inventor: Sven Loebrich
  • Patent number: 10913713
    Abstract: The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: February 9, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Michael Reardon, Richard A. Silva
  • Publication number: 20210032327
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: July 21, 2020
    Publication date: February 4, 2021
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Patent number: 10899775
    Abstract: The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: January 26, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
  • Patent number: 10898579
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: January 26, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Nicholas C. Yoder, Chen Bai, Michael Louis Miller
  • Patent number: 10875925
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: December 29, 2020
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Patent number: 10851117
    Abstract: The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: December 1, 2020
    Assignee: IMMUNOGEN, INC.
    Inventors: Michael Reardon, Richard A. Silva